Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: Baseline characteristics, previous therapies, and transition periods of the first 2,000 subjects in the PROSPECT study

Introduction: Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has demonstrated substantial efficacy in the treatment of moderate to severe psoriasis. The PROSPECT study was designed to assess previous and concomitant use of Pso treatments in 2,504 subjects receiving secukinumab and the duration of transition periods from previous treatments to secukinumab in real-life settings. Here we report the baseline characteristics and previous therapies in an interim analysis of the first 1,988 subjects.